MedTrace Logo

Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

NCT07531693 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-05-14

No results posted yet for this study

Summary

The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.

Conditions

  • HR+/HER2- Early Breast Cancer

Sponsors & Collaborators

  • Lilly Deutschland GmbH Germany

    collaborator UNKNOWN

  • AGO-B Breast Study Group

    collaborator UNKNOWN

  • Institut fuer Frauengesundheit

    lead OTHER

Principal Investigators

  • Peter A. Fasching, Prof. Dr. med. · Department of Obstetrics and Gynaecology, Uniklinikum Erlangen

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-19
Primary Completion
2026-09-30
Completion
2027-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07531693 on ClinicalTrials.gov